rocbrutinib   Click here for help

GtoPdb Ligand ID: 12875

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The structure for rocbrutinib was obtained from proposed INN list 129 (August 2023) where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2019161152A1 (Newave Pharmaceutical) [1]. LP-168 is the one lead in Newave's development pipeline that fits the profile of a potential BTK inhibitor, but whose target is undisclosed.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 14
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 145.65
Molecular weight 761.91
XLogP 2.18
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)NC1=CC(=CC=C1N2CCN(C[C@]2([H])C)C3CCOCC3)NC4=NC(=CN(C)C4=O)C5=C(CO)C(=NC=C5)N6CCN7C(=CC8=C7CC(C)(C)C8)C6=O
Isomeric SMILES [H][C@]1(C)CN(CCN1C2=CC=C(NC3=NC(=CN(C)C3=O)C4=C(CO)C(=NC=C4)N5CCN6C7=C(CC(C)(C)C7)C=C6C5=O)C=C2NC(=O)C=C)C8CCOCC8
InChI InChI=1S/C42H51N9O5/c1-6-37(53)45-32-20-28(7-8-34(32)49-14-13-48(23-26(49)2)29-10-17-56-18-11-29)44-38-41(55)47(5)24-33(46-38)30-9-12-43-39(31(30)25-52)51-16-15-50-35(40(51)54)19-27-21-42(3,4)22-36(27)50/h6-9,12,19-20,24,26,29,52H,1,10-11,13-18,21-23,25H2,2-5H3,(H,44,46)(H,45,53)/t26-/m0/s1
InChI Key OYJVFTNYBWVQHA-SANMLTNESA-N
No information available.
Summary of Clinical Use Click here for help
If LP-168 is the same compound as rocbrutinib, it has advanced to clinical assessment for potential to treat B cell malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05917964 A Food Effect Study of LP-168 Tablets in Healthy Subjects Phase 1 Interventional Guangzhou Lupeng Pharmaceutical Company LTD.
NCT04993690 A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma Phase 1 Interventional Guangzhou Lupeng Pharmaceutical Company LTD.
NCT05716087 A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma Phase 2 Interventional Guangzhou Lupeng Pharmaceutical Company LTD.